trending Market Intelligence /marketintelligence/en/news-insights/trending/_O48VAUnJT_NPqh1DkKtzw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

La Jolla's drug for low blood pressure wins FDA approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


La Jolla's drug for low blood pressure wins FDA approval

The U.S. Food and Drug Administration approved La Jolla Pharmaceutical Co.'s Giapreza to increase blood pressure in adults with septic or other distributive shock.

The agency advised that the drug can cause dangerous blood clots with serious consequences, and preventive treatment for blood clots should be used.

Shock is a life-threatening condition that occurs due to lack of blood flow and can result in organ failure and death.

La Jolla plans to make the drug available for patients in the U.S. in March 2018.